Activated immune cells undergo a metabolic switch to aerobic glycolysis akin to the Warburg effect, thereby presenting a potential therapeutic target in autoimmune disease. Dimethyl fumarate (DMF), a derivative of the Krebs cycle intermediate fumarate, is an immunomodulatory drug used to treat multiple sclerosis and psoriasis. Although its therapeutic mechanism remains uncertain, DMF covalently modifies cysteine residues in a process termed succination. We found that DMF succinates and inactivates the catalytic cysteine of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in mice and humans, both in vitro and in vivo. It thereby down-regulates aerobic glycolysis in activated myeloid and lymphoid cells, which mediates its anti-inflammatory effects. Our results provide mechanistic insight into immune modulation by DMF and represent a proof of concept that aerobic glycolysis is a therapeutic target in autoimmunity.
P ro-inflammatory stimuli induce a metabolic switch in both myeloid and lymphoid cells, leading to a Warburg-like up-regulation of aerobic glycolysis that regulates the balance between inflammatory and regulatory immune phenotypes (1, 2) . Classically activated macrophages and effector lymphocytes such as T helper 1 (T H 1) and T H 17 cells require glycolysis for their survival, differentiation, and effector functions (3) (4) (5) (6) (7) (8) (9) , whereas oxidative metabolism favors the differentiation of alternatively activated (M2) macrophages and regulatory T (T reg ) cells (10, 11) .
Dimethyl fumarate (DMF) is a serendipitously discovered immunomodulatory drug used to treat psoriasis and multiple sclerosis (MS) (12) . Although its mechanisms of action remain incompletely understood, it is known to covalently modify cysteine residues in a process termed succination (not to be confused with lysine succinylation) (fig. S1) (13, 14) . DMF succinates kelchlike ECH-associated protein 1 (KEAP1), which activates nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) to produce antioxidant and anti-inflammatory effects that nonetheless fail to fully account for the drug's actions (15) . Endogenous fumarate also succinates proteins, with a primary target being the active-site cysteine of the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (16) . Here, we show that DMF and its clinically relevant metabolite monomethyl fumarate (MMF) target GAPDH and inactivate its enzyme activity, both in vitro and after oral treatment in mice and humans. In turn, GAPDH inhibition down-regulates aerobic glycolysis in myeloid and lymphoid cells, preventing immune activation and shifting the balance between inflammatory and regulatory cell types.
To determine whether GAPDH was succinated by DMF and MMF, we performed liquid chromatography-tandem mass spectrometry (LC-MS/MS). Treatment of recombinant human GAPDH with MMF led to monomethyl succination (2-monomethyl succinyl-cysteine) at its activesite cysteine (Cys 152 in human) as well as at Cys 156 and Cys
247
, whereas DMF produced a combination of dimethyl succination (2-dimethyl succinylcysteine) and monomethyl succination at the same cysteines (table S1 and fig. S2 ). Neither of these modifications was observed at any cysteine in vehicle-treated GAPDH. In mice, oral treatment with DMF led to both monomethyl and dimethyl succination exclusively of the active-site cysteine (Cys 150 in mouse) of GAPDH purified from the spleen and brain, with no such modifications observed on other cysteines or in vehicle-treated mice ( Fig. 1A and table S1 ). Although only the monomethyl form of the drug is detected in serum (17) , our finding that dimethyl succination occurred after oral administration was consistent with prior work (18, 19) . Monomethyl succination of GAPDH Cys 152 was also identified in peripheral blood mononuclear cells (PBMCs) from MS patients treated with DMF (Fig. 1B and  table S1 ) but not on other cysteines or in PBMCs from MS patients not treated with DMF. GAPDH succination by endogenous fumarate occurred physiologically, as we identified modification by fumarate (2-succinyl-cysteine) at the active-site cysteine in vehicle-treated mice and healthy human controls ( fig. S3 ).
Covalent modification of its catalytic cysteine should irreversibly inactivate GAPDH. We found that both DMF and MMF decreased the catalytic activity of recombinant GAPDH in a dose-and time-dependent manner (Fig. 1C) . This inhibition was irreversible, as desalting failed to restore activity ( fig. S4A ). Additionally, this inhibition was mediated by active-site binding of DMF or MMF, as the drug effect was blocked by pre-incubation with 10-fold excess of GAPDH substrates ( fig.  S4B ). GAPDH inhibition was biphasic, with an initial fast phase and a secondary slow phase. We used the Kitz-Wilson method (20) to calculate the kinetics of inhibition for both phases ( fig.  S4C ). GAPDH activity was similarly inhibited in cultured mouse peritoneal macrophages (mPMs) treated overnight with 25 mM DMF (Fig. 1D) . In mice, oral treatment with DMF decreased GAPDH activity measured from both the spleen and small intestine (Fig. 1E ). This effect was particularly profound in the small intestine, which may be relevant given the role of the gut immune system in autoimmune disorders such as MS (21) .
We next asked whether GAPDH inhibition by DMF affected aerobic glycolysis in activated immune cells. Using lactate production as a proxy measure, co-treatment with DMF significantly impaired glycolysis in mPMs stimulated in vitro for 24 hours with lipopolysaccharide (LPS; 1 mg/ml) ( Fig. 2A) . MMF had a similar effect but with lower potency. The influence on glycolysis was not due to cytotoxicity ( fig. S5) . Measurements of the extracellular acidification rate revealed a similar inhibition of aerobic glycolysis by DMF and MMF in LPS-stimulated mPMs (Fig. 2B) . In activated mouse and human CD4 + lymphocytes, DMF and MMF decreased basal glycolysis, with an even greater effect on maximal glycolytic capacity ( Fig. 2C and fig. S6 ). In LPS-stimulated mPMs, treatment with DMF produced a blockade in glycolytic flux at GAPDH (Fig. 2D and fig. S7 ), providing evidence that GAPDH inactivation mediates the down-regulation of glycolysis by DMF.
DMF had no effect on glycolysis in unstimulated mPMs (Fig. 2E) , raising the possibility that DMF acts not only on GAPDH but also on the signaling pathway required for glycolytic upregulation. However, DMF had no effect on the activity of mechanistic target of rapamycin (mTOR, as measured via p70-S6 kinase phosphorylation) or levels of hypoxia-inducible factor 1a (HIF-1a) ( Fig. 2F and fig. S8 ). This selective inhibition of glycolysis in LPS-stimulated mPMs is consistent with recent evidence that GAPDH only becomes a rate-limiting enzyme when glycolysis is up-regulated in the setting of Warburg physiology (22) (23) (24) , as it is in cancer and activated immune cells. This likely explains why DMF is not generally toxic.
We also examined whether DMF affected oxidative phosphorylation (OXPHOS). DMF increased OXPHOS in mPMs under both resting and LPS-stimulated conditions ( fig. S9A ). The inhibition of glycolysis did not depend on the upregulation of OXPHOS ( fig. S9 , B and C).
We next asked whether inhibition of GAPDH and aerobic glycolysis mediated the immunologic actions of DMF. We first addressed this question in macrophages. We reproduced previous findings that both DMF and glycolytic blockade prevent classical macrophage activation (fig. S10, A to D) (3, 25) and then determined that the inhibition of cytokine production by DMF was unrelated to its effects on OXPHOS (fig. S10E). We next measured the production of interleukin (IL)-1b under low (0.5 mM) or high (10 mM) glucose concentrations and found that DMF was much less effective in the presence of high glucose (Fig. 3A) ; this result suggests that its antiinflammatory effect can be overcome by driving glycolysis higher with saturating concentrations of glucose. DMF augmented the IL-4-induced expression of arginase-1 (Arg-1), a marker of M2 alternative activation ( fig. S10F ), but the relative importance of DMF's effects on aerobic glycolysis versus OXPHOS in promoting alternative activation was not examined.
Heptelidic acid (also known as koningic acid) is a GAPDH inhibitor that binds the active site and covalently modifies the catalytic cysteine (23, 26) . The treatment of mPMs with heptelidic acid replicated the effects of DMF on IL-1b secretion (Fig. 3B ), inducible nitric oxide synthase (iNOS) expression ( Fig. 3C and fig. S11A ), and nuclear translocation of nuclear factor kB (NF-kB) ( Fig.   3D and fig. S11B ). Conversely, the overexpression of wild-type GAPDH, but not catalytically inactive GAPDH mutated at Cys 150 , mitigated the effect of DMF on IL-1b production ( Fig. 3E and fig. S12 ). Thus, the immunologic actions of DMF were replicated by GAPDH inhibition and reversed by increasing GAPDH expression.
We next examined the effects of DMF and MMF on lymphocyte differentiation and function. We T H 1 and T H 17 versus T reg cells (Fig. 4A and fig.  S13A ). Similarly, DMF and MMF inhibited both differentiation and cytokine production under T H 1-and T H 17-polarizing conditions, an effect replicated by heptelidic acid (Fig. 4, B to D, and fig.   S13B ). As reported with HIF-1a deficiency and 2-deoxyglucose treatment (11), DMF promoted T reg cell differentiation under T reg -polarizing conditions ( Fig. 4E and fig. S13B ), and both DMF and MMF reciprocally inhibited T H 17 and promoted T reg cell development under T H 17-polarizing conditions (Fig. 4F) . When added after 3 days of polarization, DMF, MMF, and low-dose heptelidic acid had no effect on the viability ( fig. S14A However, all three drugs inhibited the expression of interferon-g (IFN-g) and IL-17 (Fig. 4G) , suggesting an effect on cytokine production independent of survival and differentiation. Because GAPDH binding to mRNA underlies posttranscriptional regulation of cytokine production (9), we tested the effect of GAPDH succination on RNA binding ( fig. S15 ). Pretreatment with DMF or heptelidic acid decreased GAPDH-RNA binding, as reported with other modifications of the active-site cysteine (27 ) . This effect was small, however, as a similar decrease was produced by nicotinamide adenine dinucleotide (NAD + ) at onetenth the concentration. Thus, the alteration of such binding does not appear to underlie the immunologic actions of DMF.
Finally, to ascertain whether GAPDH inhibition produced anti-inflammatory actions in vivo, we examined the effect of heptelidic acid in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, and found that it attenuated the disease in these mice (Fig. 4H) .
By demonstrating that a known immunomodulatory drug acts by inhibiting aerobic glycolysis, our findings provide a proof of concept that metabolism is a viable therapeutic target in autoimmunity. They may also explain important observations of DMF therapy in patients. DMF differentially affects distinct lymphocyte subsets, producing lymphopenia that selectively depletes highly glycolytic effector T cells while sparing oxidative naïve T cells and T reg cells (28, 29) . Our findings suggest that the inhibition of aerobic glycolysis underlies these selective effects. It is also notable that DMF is simply a derivative of fumarate, which is a metabolic intermediate of the Krebs cycle, lying downstream of glycolysis in cellular energy production. We hypothesize that fumarate-induced inactivation of GAPDH represents an endogenous negative feedback loop. DMF-a more cell-permeable and electrophilic derivative of fumarate-may simply exploit this physiologic pathway to produce its immunologic actions (Fig. 4I) . However, additional targets of succination (in addition to KEAP1) are likely relevant to both the therapeutic and toxic effects of the drug.
